Net profit of Glenmark Life Sciences declined 17.70% to Rs 111.48 crore in the quarter ended June 2024 as against Rs 135.45 crore during the previous quarter ended June 2023. Sales rose 1.76% to Rs 588.62 crore in the quarter ended June 2024 as against Rs 578.45 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales588.62578.45 2 OPM %27.1033.39 - PBDT164.63194.62 -15 PBT150.24182.01 -17 NP111.48135.45 -18 Powered by Capital Market - Live News

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 25 July 2024.Powered by Capital Market - Live News

Net profit of Glenmark Life Sciences declined 33.08% to Rs 97.94 crore in the quarter ended March 2024 as against Rs 146.36 crore during the previous quarter ended March 2023. Sales declined 13.64% to Rs 536.60 crore in the quarter ended March 2024 as against Rs 621.32 crore during the previous quarter ended March 2023.For the full year,net profit rose 0.84% to Rs 470.89 crore in the year ended March 2024 as against Rs 466.96 crore during the previous year ended March 2023. Sales rose 5.64% to Rs 2283.21 crore in the year ended March 2024 as against Rs 2161.22 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales536.60621.32 -14 2283.212161.22 6 OPM %26.3633.22 -29.5329.72 - PBDT144.21209.15 -31 684.74670.70 2 PBT129.68197.63 -34 631.29628.61 0 NP97.94146.36 -33 470.89466.96 1 Powered by Capital Market - Live News

Glenmark Life Sciences announced that Gita Nayyar (DIN: 07128438), has tendered her resignation as a Non-Executive, Independent Director of the Company, with effect from 22 April 2024. Powered by Capital Market - Live News

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 25 April 2024.Powered by Capital Market - Live News